Revita Life Sciences Announces Second Compassionate Use IRB Approval For Multi-Modality Brain Death Protocol at New Delhi Hospital

Share Article

The approval to apply this innovative, multi-modality brain death research protocol at a second institution, a large New Delhi based hospital, represents an increasing acceptance of the area of interventional brain death research, as well as future possibilities for regenerative medicines to reverse this most severe human disorder of consciousness.

"We are confident that our small steps with our multi-modality protocol to reverse the state of brain death like this will change the outcome in these subjects in near future." - Mr.Pranjal Agrawal, CEO Revita Life Sciences.

Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it has received another compassionate use IRB approval, to apply their novel, multi-modality clinical intervention in the state of brain death in humans, this time at a hospital in New Delhi. US biotech company Bioquark Inc. (http://www.bioquark.com) is a scientific collaborator on this project

“We are very excited about this new IRB approval for our multi-modality protocol to reverse the state of brain death” said Mr. Pranjal Agrawal, CEO Revita Life Sciences. "We are confident that our small steps with this novel protocol will beneficially change the outcome of these subjects in near future."

Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.

“The fact that more institutions are accepting and coming on-line with our exploratory protocol highlights a very promising dynamic in the quest to reverse the most severe disorder of consciousness.” said Dr. Himanshu Bansal, Chief Scientific Officer, Revita Life Sciences and Director of Mother Cell. “Moving to such a multi-centered model will prove invaluable to the future evolution of the program, as well as in progressing the development multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans”.

With the maturation of the tools of medical science in the 21st century, especially cell therapies and regenerative medicines, tissues once considered irretrievable, may finally be able to be revived or rejuvenated. Hence many scientists believe that brain death, as presently defined, may one day be reversed. While the very long term goal is to find a solution for “re-infusing life”, the short term purpose of these types of studies is much less dramatic, which is to confirm if the current definition of brain irreversibility still holds true. There have been many anecdotal reports of brain death reversal across the world over the past decades in the scientific literature. Studies of this nature serve to verify and establish this very fact in a scientific and controlled manner. It will also one day give a fair chance to individuals, who are declared brain dead, especially after trauma.

About Revita Life Sciences

Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies and regenerative medicine interventions that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, Dural nerve grafts, nasal olfactory tissues, and omental transposition.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mr. Pranjal Agrawal
Visit website